US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm AbbVie Inc. (NYSE: ABBV), through which Sionna has acquired rights to two Phase II molecules and one Phase I candidate. These pipeline candidates are all modulators designed to treat cystic fibrosis (CF). The deal includes upfront and milestone payments, as well as royalties on future sales to be paid to AbbVie. Additionally, AbbVie will receive an undisclosed equity stake in Sionna.
The agreement grants Sionna exclusive global development and commercialization rights to the following CFTR modulators:
- The Phase II asset galicaftor (ABBV-2222), a transmembrane domain 1 (TMD1)-directed CFTR corrector.
- The Phase II asset navocaftor (ABBV-3067), a CFTR potentiator.
- The Phase I asset, a TMD1-directed corrector known as ABBV-2851.
This strategic deal significantly bolsters Sionna’s existing cystic fibrosis pipeline, which already includes several first-in-class nucleotide-binding domain 1 (NBD1) stabilizer molecules, the ICL4-targeted SION-109, and other TMD1 and TMD2-targeted molecules. Sionna plans to initially explore a combination approach involving one of the AbbVie compounds paired with SION-109, as well as potential dual combinations with Sionna’s NBD1 stabilizer molecules.
The collaboration with AbbVie allows Sionna to pursue a range of combination therapies for cystic fibrosis, offering new treatment possibilities for patients. The deal underscores the commitment of both companies to advancing treatments for CF and highlights the potential of partnership in driving innovation in the healthcare sector.
Sionna’s focus on developing a diverse portfolio of CFTR modulators positions the company at the forefront of CF research and development. The acquisition of AbbVie’s CF assets is expected to accelerate Sionna’s mission to bring transformative therapies to patients suffering from cystic fibrosis.- Flcube.com
